Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 17/20 | 0.60 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.59 |
| ▸ | METTL3 | Q86U44 | 5/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18922569 | 0.90 | PRMT5 (0.62) | PRMT5WDR77METTL3 | |
| SCHEMBL23776679 | 0.89 | PRMT5 (0.56) | PRMT5WDR77METTL3 | |
| SCHEMBL9913610 | 0.88 | PRMT5 (0.60) | PRMT5WDR77METTL3 | |
| SCHEMBL25956773 | 0.87 | PRMT5 (0.69) | PRMT5WDR77METTL3 | |
| SCHEMBL19540226 | 0.86 | PRMT5 (0.58) | PRMT5WDR77METTL3 | |
| SCHEMBL21937467 | 0.85 | DOT1L (0.58) | PRMT5WDR77METTL3 | |
| SCHEMBL10249394 | 0.85 | DOT1L (0.62) | PRMT5WDR77METTL3 | |
| SCHEMBL29323387 | 0.83 | PRMT5 (0.67) | PRMT5WDR77METTL3 | |
| SCHEMBL29325375 | 0.83 | PRMT5 (0.67) | PRMT5WDR77METTL3 | |
| SCHEMBL24465141 | 0.83 | PRMT5 (0.67) | PRMT5WDR77METTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210252035-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. | 2021-08-19 | — | — | US | disclosed |
| US-20200113923-A1 | DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA | Epizyme, Inc. | 2020-04-16 | — | — | US | disclosed |
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200113923-A1 | DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA | DOT1L, CARM1, MCL1 | PRMT5 18/4885WDR77 27/4885METTL3 762/4885 |
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | DOT1L, ASH1L, CARM1 | PRMT5 69/4885WDR77 31/4885METTL3 1598/4885 |
| US-20210252035-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | TPMT, DIMT1, DAZAP1 | PRMT5 37/4885WDR77 32/4885METTL3 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.